Cancer Family
Head and Neck Neoplasm
CI-CAN-00000021Explore in graph →
Non-malignant1,572 active trials17 approved drugs142 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000021Explore in graph →
Clinical trials
6,373 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05175404 | Use of 18F-PSMA-11 PET for Detection of Lesions in Iodine Refractory Thyroid Cancers | completed | Phase 2 | 8 | University Hospital, GhentOTHER | 1 | Mar 4, 2025 | clinicaltrials |
| NCT03058289 | A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6(IT-01) | completed | Phase 1 / Phase 2 | 111 | Intensity Therapeutics, Inc.INDUSTRY | 2 | Feb 27, 2025 | clinicaltrials |
| NCT03866967 | A Study of Anti-PD-1 AK105 in Patients With Metastatic Nasopharyngeal Carcinoma | completed | Phase 2 | 130 | AkesoINDUSTRY | 1 | Feb 27, 2025 | clinicaltrials |
| NCT03721757 | CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer(NICO) | completed | Phase 2 | 21 | The Clatterbridge Cancer Centre NHS Foundation TrustOTHER | 1 | Feb 25, 2025 | clinicaltrials |
| NCT00544414 | Chemotherapy Followed by Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Head And Neck Cancer | completed | Phase 2 | 31 | City of Hope Medical CenterOTHER | 0 | Feb 19, 2025 | clinicaltrials |
| NCT04357873 | Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations(PEVOsq) | completed | Phase 2 | 112 | UNICANCEROTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT00559156 | Arginine/Omega-3 Fatty Acids/Nucleotides Nutritional Supplement in Treating Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy | completed | Phase 2 | 46 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 0 | Feb 13, 2025 | clinicaltrials |
| NCT04666688 | LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 44 | PureTechINDUSTRY | 1 | Feb 12, 2025 | clinicaltrials |
| NCT02152137 | Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer | completed | Phase 2 | 19 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jan 27, 2025 | clinicaltrials |
| NCT03504488 | CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2) | completed | Phase 1 / Phase 2 | 132 | BioAtla, Inc.INDUSTRY | 6 | Jan 15, 2025 | clinicaltrials |
| NCT03518606 | Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours(MOVIE) | completed | Phase 1 / Phase 2 | 126 | UNICANCEROTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT03715946 | Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer | completed | Phase 2 | 40 | Robert L. Ferris, MD, PhDOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT04649476 | Neoadjuvant PD-1 Blockade in Resectable Oral Squamous Cell Carcinoma(NEOPBOSCC) | completed | Phase 2 | 68 | Hospital of Stomatology, Wuhan UniversityOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT04815720 | Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck(KEYNOTE-B84) | completed | Phase 1 / Phase 2 | 49 | Vaccinex Inc.INDUSTRY | 1 | Jan 8, 2025 | clinicaltrials |
| NCT02281955 | De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC: Follow-up Study | completed | Phase 2 | 115 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT02573493 | Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)(APA) | completed | Phase 2 | 96 | Washington University School of MedicineOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT04731467 | A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 79 | Famewave Ltd.INDUSTRY | 3 | Dec 27, 2024 | clinicaltrials |
| NCT03997968 | A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 169 | Cyteir Therapeutics, Inc.INDUSTRY | 1 | Dec 24, 2024 | clinicaltrials |
| NCT03946358 | Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL)(VolATIL) | completed | Phase 2 | 47 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT04996758 | Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL) | completed | Phase 2 | 40 | Sun Yat-sen UniversityOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT02538510 | Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery | completed | Phase 1 / Phase 2 | 50 | University of WashingtonOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT03878979 | Preoperative Immune Checkpoint Inhibitor for Patients With Primary Untreated or Recurrent/Metastatic SCCHN | completed | Phase 2 | 26 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT01530997 | De-intensification of Radiation & Chemotherapy in Low-Risk Human Papillomavirus-related Oropharyngeal Squamous Cell Ca | completed | Phase 2 | 45 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Nov 13, 2024 | clinicaltrials |
| NCT00248235 | Resistance Exercise Training for the Shoulder and Neck Following Surgery for Head and Neck Cancer | completed | Phase 2 / Phase 3 | 64 | University of AlbertaOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT01969578 | Androgen Deprivation Therapy in Advanced Salivary Gland Cancer | completed | Phase 2 | 149 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 8 | Nov 5, 2024 | clinicaltrials |
| NCT02609503 | Pembrolizumab + Radiation for Locally Adv SCC of the Head and Neck (SCCHN) Not Eligible Cisplatin | completed | Phase 2 | 29 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT00868491 | Induction Chemotherapy Followed by Chemoradiation With Cetuximab in Head and Neck Cancer | completed | Phase 2 | 30 | Institute of Oncology LjubljanaOTHER | 1 | Oct 18, 2024 | clinicaltrials |
| NCT03990571 | Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma | completed | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 18, 2024 | clinicaltrials |
| NCT04144517 | A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck Cancer | completed | Phase 2 | 14 | Mural Oncology, IncINDUSTRY | 1 | Oct 16, 2024 | clinicaltrials |
| NCT04895345 | A Study of TQB2450 in Combination With Intensity-modulated Radiotherapy in Patients With Inoperable Locally Recurrent Nasopharyngeal Carcinoma | completed | Phase 2 | 25 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Sep 26, 2024 | clinicaltrials |
| NCT03565003 | A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China | completed | Phase 1 / Phase 2 | 126 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 25, 2024 | clinicaltrials |
| NCT02258659 | Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer(OPTIMA) | completed | Phase 2 | 62 | University of ChicagoOTHER | 1 | Sep 24, 2024 | clinicaltrials |
| NCT03521570 | Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Cancer | completed | Phase 2 | 62 | Emory UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04220307 | A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal Carcinoma | completed | Phase 2 | 34 | AkesoINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04474470 | A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer | completed | Phase 1 / Phase 2 | 52 | TyrNovo Ltd.INDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT04721223 | JAB-3068 Activity in Adult Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 12 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03422536 | Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma | completed | Phase 2 | 78 | University of ArizonaOTHER | 1 | Sep 4, 2024 | clinicaltrials |
| NCT00720304 | Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 43 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT05865548 | Addition of Aspirin to Standard of Care in Oral Cancer | completed | Phase 2 / Phase 3 | 60 | Banaras Hindu UniversityOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT02777385 | Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer | completed | Phase 2 | 80 | Dan ZandbergOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT02776163 | Postoperative Concurrent Chemoradiotherapy in Treating Patients With High-Risk Salivary Gland Carcinomas | completed | Phase 2 | 107 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Jul 30, 2024 | clinicaltrials |
| NCT02393690 | Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer | completed | Phase 2 | 60 | Academic and Community Cancer Research UnitedOTHER | 1 | Jul 26, 2024 | clinicaltrials |
| NCT04570839 | COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors. | completed | Phase 1 / Phase 2 | 48 | Compugen LtdINDUSTRY | 1 | Jul 18, 2024 | clinicaltrials |
| NCT01064479 | Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 123 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT02383927 | Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations | completed | Phase 2 | 63 | Kura Oncology, Inc.INDUSTRY | 10 | Jul 11, 2024 | clinicaltrials |
| NCT01856920 | QUILT-3.006 for Recurrent Medullary Thyroid Cancer | completed | Phase 2 | 35 | NantCell, Inc.INDUSTRY | 1 | Jul 9, 2024 | clinicaltrials |
| NCT04541355 | Sodium Thiosulfate in Preventing Ototoxicity for Squamous Cell Cancer Patients Undergoing Chemoradiation With Cisplatin | completed | Phase 2 | 16 | Hyunseok Kang, MDOTHER | 1 | Jun 28, 2024 | clinicaltrials |
| NCT03719690 | Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy(AIM-HN/SEQ-HN) | completed | Phase 2 | 296 | Kura Oncology, Inc.INDUSTRY | 16 | Jun 21, 2024 | clinicaltrials |
| NCT02923258 | Postoperative CCRT With Docetaxel vs Cisplatin in High Risk Oral Cavity Cancer | completed | Phase 2 / Phase 3 | 224 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Jun 20, 2024 | clinicaltrials |
| NCT04107103 | Nivolumab Plus Pemetrexed for Head and Neck Squamous Cell Carcinoma(NivoPlus) | completed | Phase 2 | 6 | AHS Cancer Control AlbertaOTHER | 1 | Jun 14, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Mar 4, 2025source: clinicaltrials